Jean-Marc Guedon

Excited to announce the 2025 Gordon Research Conference (GRC) on Protein Engineering, this second GRC on Protein Engineering will be held at Bryant University in Smithfield, RI from July 27th to August 1st 2025 https://lnkd.in/g-763SeF. please come join us if you would be interested in this exciting field. Different fields have experienced a transformative expansion in research distinction and capabilities. There now exists a strategic opportunity for protein engineering to take the lead and spearhead the integration of this joint effort, reflected by The Nobel Prize in Chemistry 2024. We believe that this GRC conference will create a gateway for the next generation of engineers and researchers, and will be a vehicle toward future development in the midst of an amazing convergence of multiple cutting-edge areas in protein engineering and its applications. Confirmed speakers include the Nobel Laureate Prof. Frances Arnold and distinctive scientists showing below: 1.            Fundamental Principles of Protein Engineering Possu Huang (Stanford University)/Frances Arnold (CalTech, Nobel Laureate)/Huimin Zhao (University of Illinois at Urbana-Champaign) 2.    Biosensors and Imaging Jennifer Prescher (UC Irvine)/Jin zhang (UC San Diego)/Robert Campbell (Tokyo University)/Nathan Shaner (UC San Diego) 3.    Rational Design of New-to Nature Proteins Jiri Damborsky (FNUSA-ICRC & Masaryk University, Czech Republic)/Joelle Pelletier (University of Montreal)/Sílvia Osuna (University of Girona & ICREA, Spain)/Koga Nobuyasu (Osaka Univ, Japan) 4.    AI for Protein engineering Zhongyue John Yang (Vanderbilt University)/ Jennifer Listgarten (UC Berkeley)/Doug Barrick (Johns Hopkins University) 5.    Biocatalysis and Industrial applications Carlos Martinez (Pfzer)/ Stephanie Galanie (Merck)/Zhi Li (National University of Singapore, Singapore)/Brent Dorr (Ginkgo Bioworks) 6.    Protein Engineering for Synthetic Biology Pimchai Chaiyen (Vidyasirimedhi Institute of Science and Technology (VISTEC), Thailand)/Weixin Tang (University of Chicago)/Jay Keasling (University of California, Berkeley) 7.    Directed Evolution for Enzyme Optimization Yang Yang (University of California Santa Barbara)/Leilei Zhu (Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, China)/Miguel Alcalde (Institute of Catalysis, CSIC, Spain)/Chang Liu (University of California, Irvine) 8.    Protein engineering for Immunotherapy and other diseases Anna Wu (Beckman Research Institute, City of Hope)/Xue Gao (University of Pennsylvania)/Bingfei Yu (University of Southern California)/Wilson Wong (Boston University) 9.    Repurposing Protein for Novel Chemistry and Applications Stefan Lutz (Codexis Inc)/Xiongyi Huang (Johns Hopkins University)/Xiaojing Gao (Stanford University)

46

3 Comments

digiM's recent FDA IDIQ contract award marks a big step in advancing the role of microstructure analysis in regulatory assessment for complex generics. This partnership is set to deepen industry knowledge around product quality attributes and release mechanisms in key drug products, from injectables to implants. This recognition highlights the growing impact of microstructure tools like 3D microscopy and AI-based modeling, demonstrating how essential microstructure science is becoming within the pharmaceutical industry. https://lnkd.in/d5sj5Eds

8

Hey Boston friends! I'll be in town next week! If you want to chat about #hPSCs in any way shape or form, let me know! Would be great to have a conversation about how STEMCELL Technologies can help. #BostonScience #BostonBiotech #BostonLifeSciences #StemCellResearch #RegenerativeMedicine #Biotechnology #LifeSciences #hPSCResearch #ScienceInnovation #ScientificCollaboration #NetworkingOpportunities #InnovationInScience

28

https://lnkd.in/etB2Pmqt : a new compound called TRanscriptional Activator of p53 (TRAP-1) is able to engage p53-Y220C and BRD4 in a ternary complex, which potently re-activates mutant p53, resulting in rapid upregulation of p21 and other p53 target genes and inhibits the growth of p53Y220C-expressing cell lines.

8

The basics of the overall T cell signaling pathway. https://lnkd.in/eDH95adg

6

I had the pleasure of reading some recent ASAP articles for ACS Med Chem Lett. They are super quick reads and cover a broad range of interesting topics. I wrote the recent "In This Issue" on 3 of my favorites:

10

Amgen IPP strikes again! Led by the talented Dhanusha Nalawansha and P. Ryan Potts, Ph.D., our team has developed a novel promixity induced modality called LYMTACs. LYMTACs are heterobifunctional small molecules that recruit proteins of interest to the lysosome by co-opting lysosomal resident proteins. This technology is especially effective for membrane targets and offers a "double whammy" mechanism of action: it degrades the target of interest or relocates and traps it to the lysosome. Learn how we applied LYMTACs to target mutant KRAS where we showcase the benefit of this novel approach over traditional modalities. Congrats to all co-authors and collaborators. https://lnkd.in/gN_jxAGQ

74

1 Comment

An Automated High-throughput Affinity Capture Mass Spectrometry Platform with Data Independent Acquisition A recent manuscript from researchers Hui Jing, Paul Richardson, Gregory Potts, Sameera Senaweera, Violeta Marin, Ryan McClure, Adam Banlasan, Hua Tang, James Kath, Renze (Arthur) Ma, and Jon Williams from AbbVie discusses the development, optimization, and application of a streamlined #chemoproteomics workflow Key Points: - #Automation of a workflow employing biotinylated probes and streptavidin magnetic beads for small molecule target enrichment has been developed to overcome the challenge of tedious and time-consuming sample preparation by leveraging the Integra Assist Plus from INTEGRA Biosciences. - A data-independent acquisition (#DIA) MS method was developed to establish a label-free quantitative chemical proteomic kinome profiling workflow leveraging the Evosep One platform from Evosep Biosystems and #Orbitrap Exploris 480 from Thermo Fisher Scientific. - Advancements in ultra-fast and sensitive MS instrumentation yields the possibility to perform miniaturized affinity capture and increase throughput to 100 SPD or faster. The full manuscript can be read here https://lnkd.in/gX2PhDMT To learn more about the Evosep One platform, visit our website www.evosep.com or reach out to me for more information.

53

Affinity, in-pen assays, in-channel assays, sequential assays, cell export, etc - on the same cell in a single chip? If you want to know more - join Vincent Pai and the team at PEGS conference in Boston! #antibodydiscovery #antibodyblocking #affinity #vaccinedevelopment #neutralizingantibodies #IgG #IgM

8

This is always and informative and useful resource.

13

Happy Friday all! Check out this open access Nature Scientific Reports article by Abali et al., "A nanowell platform to identify, sort and expand high antibody-producing cells." https://lnkd.in/gMuJNSxf Abstract: Increased use of therapeutic monoclonal antibodies and the relatively high manufacturing costs fuel the need for more efficient production methods. Here we introduce a novel, fast, robust, and safe isolation platform for screening and isolating antibody-producing cell lines using a nanowell chip and an innovative single-cell isolation method. An anti-Her2 antibody producing CHO cell pool was used as a model. The platform; (1) Assures the single-cell origin of the production clone, (2) Detects the antibody production of individual cells and (3) Isolates and expands the individual cells based on their antibody production. Using the nanowell platform we demonstrated an 1.8–4.5 increase in anti-Her2 production by CHO cells that were screened and isolated with the nanowell platform compared to CHO cells that were not screened. This increase was also shown in Fed-Batch cultures where selected high production clones showed titers of 19–100 mg/L on harvest day, while the low producer cells did not show any detectable anti-Her2 IgG production. The screening of thousands of single cells is performed under sterile conditions and the individual cells were cultured in buffers and reagents without animal components. The time required from seeding a single cell and measuring the antibody production to fully expanded clones with increased Her-2 production was 4–6 weeks. #drugdiscovery #antibodies #cancerresearch #immunotherapy #immunooncology #scientificresearch

11

CicrRNA 2.0. This paper from the Wang lab @ MIT finds that a branched mRNA cap effectively initiates translation on linear or circular #mRNAs without IRES. Two types of chemical modification, locked nucleic acid (LNA) N7-methylguanosine modifications on the cap and LNA + 5 × 2′ O-methyl on the 5′ untranslated region, enhance RNA–eukaryotic translation initiation factor (eIF4E–eIF4G) binding and RNA stability against decapping in vitro. Through multidimensional chemotopological engineering of dual-capped mRNA and capped circular RNA, we enhanced mRNA protein production by up to tenfold in vivo, resulting in 17-fold and 3.7-fold higher antibody production after prime and boost doses in a severe acute respiratory syndrome coronavirus 2 vaccine setting, respectively.  https://lnkd.in/eX2a9Tn3

105

1 Comment

Check out this new exciting review article from Amgen about RNATAC!

12

Nice in depth (and nostalgic) analysis of the new Illumina SmolSeq (🐱) by Keith Robison. Some really insightful points, most importantly IMO that SmolSeq is artfully positioned to create some competitive turbulence for Element Biosciences: "But now, $50K gets a very highly performing machine and $100K one which will fit many startup aspirations.  AVITI is still a sweet instrument, but Illumina just made that conversation more complicated." Also, why so shy about a DX version - "But even more surprising is that Illumina didn't outline a clear roadmap for clinical versions of the MiSeq i100 [🐱] - the DX model of the MiSeq received FDA clearance. The simpler workflows and smaller footprint would seem to make MiSeq i100 [🐱] a natural to try to put into pathology labs. So why the hesitancy to outline a path to get these into lucrative clinical markets?"

78

16 Comments

Less than a month and counting . . . The growing demand for recombinant proteins requires simultaneous strategic development, application, and adoption of tools for the efficient expression and production of these valuable biomolecules. The Expression Stream at #PEGSEurope tackles these issues head on. https://lnkd.in/eaVu6nnZ ◼ SHORT COURSE: Tools for Cell Line Engineering and Development – what are the future tools for CLE and CLD? ◼ TRAINING SEMINAR: Current Applications of Host Expression Systems and Optimisation of the CEPA Workflow to Support Therapeutic Generation and Structural Biology – applying CEPA (Cloning, Expression, Purification, Analytics) to your workflow process? ◼ CONFERENCE: Using Data Science to Maximise Protein Production – how are you using data and engineering to evaluate expression hosts? ◼ CONFERENCE: Optimising Expression Platforms - what is the best expression system for producing your recombinant protein of choice? ◼ CONFERENCE: Protein Process Development - what are your throughput goals? These strategic back-to-back meetings investigate the newest data, innovations, and strategies to make the expression of therapeutic proteins more efficient, effective and trouble-free. #biopharmaceuticals #proteinexpression #proteinpurification #Barcelona

27

2 Comments

I wanted to congratulate my coauthors Rashmi Madda, Haichuan Liu and Zoe Zhang on a great technote about multilevel analysis of MMAE conjugated Trastuzumab using Genovis' GlyCLICK® chemistry. Combining the ZenoTOF 7600 with both the Intabio ZT and EAD peptide mapping, comprehensive intact and localized characterization of modifications were achieved. Comparisons between pre and post derivatized Trastuzumab samples identified natural and synthetic modifications allowing for highly accurate monitoring of the payload conjugation reactions. For those interested follow the link below for a PDF copy of the technote https://lnkd.in/eSreFYCz

39

While everyone's been focused on T cell engagers, Innate Pharma's quietly developed something rather clever: a tetraspecific antibody that turns NK cells into a precision cancer-fighting force. The science here is fascinating - their IPH6501 molecule simultaneously engages three NK cell receptors (including an IL-2 variant for proliferation) plus CD20 on B-cell lymphomas. It's like creating a molecular matchmaker that not only brings NK cells to their target but ensures they're properly activated and can multiply once they get there. What's particularly interesting about this approach: - Potentially better safety profile than T cell engagers - Multiple NK activation signals in one molecule - Demonstrated efficacy in both mice and primates And all this while other companies are stepping back from NK cell therapies. From "natural" killers to "precision-guided" killers 🎯 #CancerImmunotherapy #NKcells #AntibodyEngineering #Lymphoma ------------------- Hi, I'm James - I post about all things immuno-oncology. I am Vice President of Sales at ichorbio, a bulk manufacturer of in vivo antibodies and research biosimilars. If you like my content please reshare with your network and follow me to see more!

17